Sleep Review
  • Disorders
    • Breathing Disorders
    • Insomnia
    • Hypersomnias
    • Movement Disorders
    • Circadian Rhythm Disorders
    • Parasomnias
  • Diagnostics
    • Screeners
    • In-Lab Tests
    • Home Based/Out of Lab
    • Connected Care
    • Consumer Sleep Tracking
  • Treatments
    • Therapy Devices
    • Pharmaceuticals
    • Surgeries & Procedures
    • Behavioral Sleep Medicine
  • Health
    • Parameters
    • Demographics
    • Sleep & Body Systems
    • Prevailing Attitudes
  • Practice Management
    • Money
    • Laws & Regulations
    • Marketing
    • Human Resources
  • Earn CEC
  • Resources
    • Podcasts
    • Webinars
    • White Papers
    • Videos
  • Digital Edition

Select Page

Tag: Daridorexant

All

Latest
Idorsia Reports Q1 2026 Results, Highlighting Pediatric Daridorexant Data and Expanding Clinical Evidence

Idorsia Reports Q1 2026 Results, Highlighting Pediatric Daridorexant Data and Expanding Clinical Evidence

The company’s first-quarter update emphasizes strong phase 2 results for daridorexant in children, ongoing real-world studies in patients with co-morbidities, and advancements in its sleep medicine pipeline.

  • Idorsia Reports Strong 2025 Financials with QUVIVIQ Sales More Than Doubling

  • Insomnia Drug Daridorexant Begins Phase 3 Study to Support South Korea Approval

  • Daridorexant for Insomnia Nears Approval in Japan

  • Health Canada Approves Quviviq Insomnia Medication

  • Insomnia Medication QUVIVIQ Receives FDA Approval

  • Daridorexant Shows Promise as Insomnia Therapy

All

Latest

Idorsia Picks Commercialization Partner for Insomnia Drug Candidate

The collaboration brings Idorsia’s daridorexant and expertise in the science of the orexin system together with Syneos Health’s customer-facing sales expertise and track record.

  • Investigational Insomnia Drug Improves Daytime Functioning in Phase 3 Study

    Investigational Insomnia Drug Improves Daytime Functioning in Phase 3 Study

  • Phase 3 Study Results of Investigational Dual Orexin Receptor Antagonist for Insomnia to Be Presented at SLEEP 2020

    Phase 3 Study Results of Investigational Dual Orexin Receptor Antagonist for Insomnia to Be Presented at SLEEP 2020

  • Phase 3 Study: Idorsia’s Dual Orexin Receptor Antagonist Improves Sleep in Insomnia Patients

    Phase 3 Study: Idorsia’s Dual Orexin Receptor Antagonist Improves Sleep in Insomnia Patients

All

Latest
Sorry, No Posts Found
Sorry, No Posts Found

Sleep Review

7300 W 110th St – Floor 7
Overland Park, KS 66210

Our Parent Company

MEDQOR LLC

About MEDQOR

MEDQOR Data Platform

Media Solutions Kit

Press Releases

Key Resources

Digital Edition

Podcasts

Webinars

White Papers

Videos

Helpful Links

Submit a Press Release

Advisory Board

Submit an Article

Subscribe

Contact Us

  • Follow
  • Follow
  • Follow
  • Follow

Copyright

Privacy Policy

Terms of Service

© 2026 MEDQOR LLC. All Rights Reserved

✖